LifeMD, Inc. reported second quarter 2026 financial results on August 5, 2026, with revenue of $47.3 million and an adjusted EBITDA loss of approximately $3.5 million. The company revised its full-year 2026 guidance to revenue of $205.5 million to $212.5 million and adjusted EBITDA between negative $6.0 million and breakeven, citing launch costs for XYOSTED®. Active subscribers grew 20% year-over-year to approximately 356,000, while gross margin expanded to approximately 89%. LifeMD exited the quarter with $25.1 million in cash, no debt, and a $30 million undrawn revolving credit facility.